SCHEMBL418240

SCHEMBL418240

CCOC(=O)c1cc(Br)c(Br)o1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.46
HDAC4 P56524 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
MAPT P10636 3/20 0.44
TSHR P16473 3/20 0.44
MAOB P27338 2/20 0.44
ALOX15 P16050 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42
GAA P10253 2/20 0.41
PKM P14618 2/20 0.41
NR1H2 P55055 1/20 0.41
NR1H3 Q13133 1/20 0.41
MAPK1 P28482 1/20 0.40
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10102792 0.86 AKR1B1 (0.46) AKR1B1HDAC4HDAC6MAPTTSHR
SCHEMBL12086844 0.80 HDAC4 (0.44) AKR1B1HDAC4HDAC6MAPTTSHR
SCHEMBL1198786 0.79 MAPT (0.50) MAPTTSHRHSD17B10CA12CA1
SCHEMBL68855 0.76 HDAC4 (0.53) AKR1B1HDAC4HDAC6MAPTTSHR
SCHEMBL417915 0.75 MAPT (0.45) AKR1B1HDAC4HDAC6MAPTPKM
SCHEMBL26244629 0.74 MAOB (0.52) AKR1B1HDAC4HDAC6MAPTTSHR
SCHEMBL21230746 0.74 MAOB (0.52) AKR1B1MAPTTSHRMAOBALOX15
SCHEMBL31571741 0.74 TAS1R3 (0.49) AKR1B1HDAC4HDAC6MAPTTSHR
SCHEMBL931020 0.73 MAOB (0.51) AKR1B1MAPTTSHRMAOBHSD17B10
SCHEMBL21230503 0.73 MAOB (0.51) AKR1B1HDAC4HDAC6MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2376479-B1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO KG (DE) 2016-03-02 EP disclosed
US-8324268-B2 Substituted furancarboxamides, and use thereof AICURIS GMBH & CO. KG (DE) 2012-12-04 US disclosed
US-8324268-B2 Substituted furancarboxamides, and use thereof AICURIS GMBH & CO. KG (DE) 2012-12-04 US disclosed
US-8324268-B2 Substituted furancarboxamides, and use thereof AICURIS GMBH & CO. KG (DE) 2012-12-04 US disclosed
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
WO-2010075957-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AADAC, DDC, TPMT AKR1B1 2088/4885HDAC4 1252/4885HDAC6 1786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.